Skip to main navigation

Top Bar

info@eledon.com
+1 949.238.8090

Search for:

Main navigation

Home
About Us
R&D
Investors
Join the team
Contact Us

Investors

Investor Relations

Investors
News
Events
Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor FAQs
Contact Investor Relations
Ethics Hotline

Presentations

Corporate Presentations

Eledon Corporate Presentation

ALS Phase 2a Clinical Trial Update Presentation

Eledon Pharmaceuticals R&D Day Presentation

Scientific Presentations

2021 International Pancreas and Islet Transplantation Association Congress

A Phase 2 Safety and Tolerability Study of an Anti CD40L Antibody, AT-1501 in Adults with ALS

2021 American Transplant Congress

The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function

Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques

CSS

Toolkit

Print Page

Email Alerts

RSS Feeds

Contact

Footer

Quick links

Home
About Us
CD40L Pathway
Pipeline
AT-1501
KLH Challenge
Contact Us

Footer Investor Links

Investors
Press Releases
Governance
Stock Information
SEC Filings
Investor Email List

© 2023 Eledon Pharmaceuticals, Inc. - All Rights Reserved.